Skip to main content

Table 2 Baseline clinical characteristics

From: Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency

 

Low Potency

High Potency

Mean (SD)

E/S 10/20

(n = 189)

R 10

(n = 180)

Total

(N = 369)

E/S 10/20

(n = 125)

R 10

(n = 124)

Total

(N = 249)

LDL-C (mg/dL)

125.2 (16.3)

124.2 (16.7)

124.7 (16.5)

121.2 (15.7)

126.7 (16.6)

123.9 (16.3)

HDL-C (mg/dL)

55.9 (15.1)

55.0 (13.7)

55.4 (14.4)

54.7 (12.9)

55.0 (13.6)

54.9 (13.2)

non-HDL-C (mg/dL)

153.0 (21.4)

150.5 (21.1)

151.8 (21.2)

150.4 (21.0)

156.0 (21.6)

153.1 (21.5)

TC (mg/dL)

208.9 (22.7)

205.5 (22.6)

207.2 (22.7)

205.1 (21.2)

210.9 (23.4)

208.0 (22.4)

TG (mg/dL)*

125.0 (72.6)

116.0 (68.8)

121.0 (70.7)

134.5 (75.3)

135.0 (77.7)

135.0 (75.3)

Apo B (mg/L)

119.4 (19.5)

115.4 (21.7)

117.4 (20.7)

119.3 (20.1)

122.4 (18.5)

120.8 (19.4)

hs-CRP (mg/L)*

1.7 (2.7)

1.4 (2.2)

1.6 (2.5)

1.4 (2.1)

1.6 (2.9)

1.6 (2.4)

LDL-C/HDL-C

2.4 (0.7)

2.4 (0.7)

2.4 (0.7)

2.3 (0.6)

2.4 (0.7)

2.4 (0.6)

TC/HDL-C

3.9 (0.9)

3.9 (0.9)

3.9 (0.9)

3.9 (0.9)

4.0 (0.9)

4.0 (0.9)

  1. Apo B = apolipoprotein B; E = ezetimibe; hs-CRP = high-sensitivity C-reactive protein; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; R = rosuvastatin; S = simvastatin; TG = triglycerides; TC = total cholesterol
  2. *presented as median values with standard deviation (SD) calculated by (Q3-Q1)/1.075